Concord Biotech Limited (NSE:CONCORDBIO)

Market Cap	146.11B
Revenue (ttm)	10.89B
Net Income (ttm)	3.26B
Shares Out	104.62M
EPS (ttm)	31.19
PE Ratio	44.78
Forward PE	34.53
Dividend	8.75 (0.63%)
Ex-Dividend Date	n/a

Volume	230,699
Average Volume	114,738
Open	1,386.70
Previous Close	1,386.70
Day's Range	1,375.00 - 1,433.00
52-Week Range	1,327.05 - 2,664.00
Beta	n/a
RSI	28.08
Earnings Date	May 23, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,377
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In 2023, Concord Biotech's revenue was 10.17 billion, an increase of 19.20% compared to the previous year's 8.53 billion. Earnings were 3.08 billion, an increase of 28.33%.